Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Status unknown · Phase 4 · NCT05322070
Conditions: Uveitis, Posterior
At a glance
- Research payments reported, 2025
- $161,074
- U.S. investigators named
- 14
- Sites paid
- 13
- Planned or actual enrollment
- 125
About the trial
- Sponsor
- Alimera Sciences (with CBCC Global Research)
- Tested
- Fluocinolone Acetonide Intravitreal Implant 0.18 mg (drug)
- Dates
- Started 2022-06-06; completion 2025-11
- Results posted
- Not yet
A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.
From ClinicalTrials.gov, last updated 2024-08-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ani Pharmaceuticals, Inc. reported $161,074 in research payments for this study in 2025 (75 payments).
Products named: Yutiq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Payam Amini, M.D Retina Specialist · Pasadena, CA
- Sarju S. Patel, M.D. MSC Ophthalmology · Sacramento, CA
- Kent W. Small, MD Ophthalmology · Glendale, CA
- Mark S. Dacey, MD Ophthalmology · Denver, CO
- Ahmad B. Tarabishy, MD Ophthalmology · Wesley Chapel, FL
- Eduardo Uchiyama, M.D. Retina Specialist · Ft Lauderdale, FL
- Veena R. Raiji, MD, MPH Retina Specialist · Chicago, IL
- David J. Warrow, M.D. Ophthalmology · Hagerstown, MD
- Joseph D. Boss, M.D. Ophthalmology · Grand Rapids, MI
- Mujtaba A. Qazi, M.D. Ophthalmology · Chesterfield, MO
- Marina Gilca, MD Retina Specialist · Fargo, ND
- David R. Almeida, MD, MBA, PHD Ophthalmology · Erie, PA
- Akshay S. Thomas, M.D. Retina Specialist · Nashville, TN
- Christopher R. Henry, MD Ophthalmology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Illinois Retina Associates $31,633
- Tennessee Retina PC $28,802
- Retina Group of Florida $23,499
- Retina Consultants of Texas $21,023
- The Clinical Trials Network LLC $16,809
- Vitreo-Retinal Medical Group Inc Vrmg $10,908
- Macula and Retina Institute $10,350
- Retina Specialist of Tampa $7,837
- Foundation of Vision Research $3,698
- Midwest Vision Research Foundation $2,986
- Cumberland Valley Retina Consultants $1,250
- Azul Vision $1,250
- Colorado Retina Associates $1,028
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.